Results 261 to 270 of about 193,970 (395)

Zanidatamab in HER2-Positive Metastatic Biliary Tract Cancer: Final Results From HERIZON-BTC-01.

JAMA Oncol
Pant S, Fan J, Oh DY, Choi HJ, Kim JW, Chang HM, Bao L, Sun HC, Macarulla T, Xie F, Metges JP, Ying J, Bridgewater J, Lee MA, Tejani MA, Chen EY, Wasan H, Ducreux M, Bao Y, Wu X, Zhao Y, Garfin PM, Gable J, Harding JJ, HERIZON-BTC-01 Study Group.   +24 more
europepmc   +1 more source

Advanced Biliary Tract Cancer: Exploration of Third-Line and Other Therapeutic Areas After Failure of Chemotherapy Alone. [PDF]

Cancers (Basel)
Ma L, Yi C.
europepmc   +1 more source

Splenic artery aneurysms occurring in liver transplant recipients [PDF]

, 1991
Bronsther, O, Merhav, H, Starzl, TE, Van Thiel, D   +3 more
core   +1 more source

A Population‐Based Matched Cohort Study of Extra‐Digestive Cancer Incidence and Mortality in Individuals With and Without Inflammatory Bowel Disease

Alimentary Pharmacology &Therapeutics, EarlyView.
This illustration summarises our primary findings highlighting the rising incidence of certain extra‐digestive cancers among persons with IBD over the 25‐year study duration (left), and the relative rates of extra‐digestive cancer incidence and mortality among persons with IBD in recent years (2010–2019) compared to their age‐ and sex‐matched controls (
Sanjay K. Murthy, Faria Ahmed, Michael Pugliese, Monica Taljaard, Parul Tandon, Priscilla Matthews, Gilaad G. Kaplan, Stephanie Coward, Charles N. Bernstein, Eric I. Benchimol, M. Ellen Kuenzig, Laura E. Targownik, Harminder Singh, on behalf of the Canadian Gastro‐Intestinal Epidemiology Consortium (CanGIEC)   +13 more
wiley   +1 more source

The impact of Foxp3+ regulatory T‐cells on CD8+ T‐cell dysfunction in tumour microenvironments and responses to immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitors (ICIs) have been a breakthrough in cancer therapy, inducing durable remissions in responding patients. However, they are associated with variable outcomes, spanning from disease hyperprogression to complete responses with the onset of immune‐related adverse events.
Mikhaël Attias, Ciriaco A. Piccirillo
wiley   +1 more source

SEOM-GEMCAD-TTD clinical guidelines for biliary tract cancer (2025). [PDF]

Clin Transl Oncol
Macarulla T, Adeva J, Cano Osuna MT, Ruiz Casado A, Jiménez Gordo AM, Lamarca A, López Muñoz AM, Pazo Cid RA, Saurí T, Gallego Plazas J.   +9 more
europepmc   +1 more source

Endoscopic Ultrasound‐Directed Transgastric ERCP in Patients With Roux‐En‐Y Gastric Bypass: A Multicenter Prospective Cohort Study (EDGE‐Pilot)

Digestive Endoscopy, EarlyView.
ABSTRACT Objectives Endoscopic retrograde cholangiopancreatography (ERCP) is frequently indicated in patients who underwent Roux‐en‐Y gastric bypass (RYGB) surgery. Endoscopic ultrasound‐directed ERCP (EDGE) is a technique that is used to create a gastro‐gastrostomy by placing a lumen‐apposing metal stent (LAMS) between the gastric pouch and the ...
A. G. Overdevest, S. Haal, J. E. van Hooft, A. Inderson, S. D. Kuiken, W. O. A. Rohof, J. M. Vrolijk, M. C. B. Wielenga, T. Wijnands, R. L. J. van Wanrooij, R. P. Voermans   +10 more
wiley   +1 more source

Global burden of early-onset gallbladder and biliary tract cancer from 1990 to 2021. [PDF]

BMC Gastroenterol
Liu J, Fang W, He X, Zhang X, Liu H.
europepmc   +1 more source

Liver Transplantation in the World: Present Conditions of Liver Transplantation from Cadaver Donors in USA. [PDF]

, 1995
Marino, Ignazio Roberto, Starzl, Thomas E   +1 more
core  

Artificial Intelligence in Digestive Endoscopy Training—The Past, Present, and Future

Digestive Endoscopy, EarlyView.
AI may enhance endoscopy training through improved detection, guidance and evaluation, but demands careful implementation, validation and ethical governance to maximize benefits. ABSTRACT Background and Objective Artificial intelligence (AI) is reshaping gastrointestinal endoscopy, yet its role in training remains unexplored.
Jacky C. L. Ho, Zhouyao Qian, Louis H. S. Lau, Hon‐Chi Yip, Philip W. Y. Chiu   +4 more
wiley   +1 more source